Research programme: synthetic cannabinoid therapeutics - Kalytera Therapeutics

Drug Profile

Research programme: synthetic cannabinoid therapeutics - Kalytera Therapeutics

Alternative Names: K-1012; K-1022; K-1032; K-1052; K-436; K-671; KAL 439; KAL 671; Synthetic fatty acid amide - Kalytera Therapeutics

Latest Information Update: 24 May 2017

Price : $50

At a glance

  • Originator Hebrew University of Jerusalem
  • Developer Kalytera Therapeutics; Tel Aviv University
  • Class Cannabinoids; Fatty acids; Obesity therapies; Small molecules
  • Mechanism of Action Bone development modulators; Bone resorption factor inhibitors; Cannabinoid receptor CB1 antagonists; Osteoclast inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Fracture; Obesity; Osteogenesis imperfecta; Osteoporosis; Prader-Willi syndrome
  • Research Acne vulgaris; Respiratory distress syndrome; Sepsis; Ulcerative colitis

Most Recent Events

  • 26 Apr 2017 Kalytera Therapeutics has patents pending for the composition of matter and method of use of cannabinoid therapeutics
  • 17 Apr 2017 Early research in Acne vulgaris in USA
  • 17 Apr 2017 Early research in Respiratory distress syndrome in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top